NKTX Nkarta, Inc. Stock Quote

NKTX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.81	Insider Own	0.90%	Shs Outstand	32.99M	Perf Week	13.34%
Market Cap	622.50M	Forward P/E	-	EPS next Y	-2.89	Insider Trans	-	Shs Float	20.89M	Perf Month	-8.57%
Income	-92.70M	PEG	-	EPS next Q	-0.61	Inst Own	55.60%	Short Float	26.24%	Perf Quarter	10.08%
Sales	-	P/S	-	EPS this Y	51.80%	Inst Trans	8.77%	Short Ratio	1.67	Perf Half Y	-8.21%
Book/sh	6.93	P/B	1.99	EPS next Y	-3.60%	ROA	-31.40%	Target Price	46.50	Perf Year	-53.07%
Cash/sh	4.79	P/C	2.87	EPS next 5Y	-	ROE	-35.70%	52W Range	7.55 - 40.64	Perf YTD	-10.36%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-65.16%	Beta	-
Dividend %	-	Quick Ratio	20.60	Sales past 5Y	-	Gross Margin	-	52W Low	87.55%	ATR	1.01
Employees	135	Current Ratio	20.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	57.80	Volatility	7.20% 7.82%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-33.10%	Profit Margin	-	Rel Volume	0.05	Prev Close	13.76
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 AMC	Payout	-	Avg Volume	3.28M	Price	14.16
Recom	1.70	SMA20	9.34%	SMA50	0.37%	SMA200	-1.63%	Volume	19,076	Change	2.91%

Mar-11-22

Initiated

Raymond James

Outperform

$17

Mar-08-22

Initiated

H.C. Wainwright

Buy

$25

Jan-06-22

Initiated

William Blair

Outperform

Nov-18-21

Initiated

SMBC Nikko

Outperform

$50

Jul-16-21

Initiated

Oppenheimer

Outperform

$75

Aug-04-20

Initiated

Stifel

Buy

$41

Aug-04-20

Initiated

Mizuho

Buy

$34

Aug-04-20

Initiated

Evercore ISI

Outperform

$55

Aug-04-20

Initiated

Cowen

Outperform

Jun-14-22 07:14AM	What Is The Ownership Structure Like For Nkarta, Inc. (NASDAQ:NKTX)? Simply Wall St.
Jun-07-22 09:55AM	Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know Zacks
May-31-22 07:02AM	Nkarta to Participate at Upcoming Investor Conference GlobeNewswire +6.49%
May-18-22 12:00PM	What Makes Nkarta, Inc. (NKTX) a New Buy Stock Zacks -5.29%
09:55AM	Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect? Zacks
May-16-22 04:02PM	Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development GlobeNewswire
May-12-22 04:02PM	Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire
May-09-22 04:02PM	Positive Clinical Results Put Nkarta Stock on the Fast Track InvestorPlace -12.95%
May-06-22 05:30PM	MiMedx Group and Inozyme Stock See Action From Activist Investors Barrons.com -7.28%
May-02-22 10:45AM	Novartis Is Looking for Deals. Are These 3 Biotechs on Its List? Motley Fool
Apr-28-22 04:01PM	Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters Full Exercise of Option to Purchase Additional Shares GlobeNewswire
10:18AM	Up 131% in a Day, Is This Hot Stock a Buy? Motley Fool
Apr-25-22 11:19PM	Nkarta Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire +140.93%
06:04PM	Nkarta Scores Huge Gain on Cancer Treatment Results GuruFocus.com
05:44PM	Why this Peninsula cancer drug maker's stock soared more than 100% American City Business Journals
04:09PM	How Nkarta Stock Doubled On Its 'Natural Killers' In Blood Cancer Investor's Business Daily
04:01PM	Nkarta Announces Proposed Public Offering of Common Stock GlobeNewswire
03:52PM	Second Amazon warehouse begins union vote, Sirius XM inks deal with former NFL star Yahoo Finance Video
10:49AM	Nkarta stock skyrockets on heavy volume after upbeat results from cancer-treatment trial MarketWatch
08:34AM	Nkarta's stock jumps 42% after announcing positive Phase 1 data for experimental CAR-NK therapies MarketWatch
08:19AM	Midday Stock Movers: Twitter, Snowflake, Deere Investing.com
07:12AM	Nkarta Stock Surges on Positive Preliminary Data from Natural Killer Cell Programs Investing.com
07:00AM	Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs GlobeNewswire
Apr-22-22 04:10PM	Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates GlobeNewswire
Apr-17-22 08:54AM	Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Apr-08-22 01:25PM	Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022 GlobeNewswire -6.73%
07:58AM	Nkarta to Participate at Upcoming Investor Conference GlobeNewswire
Apr-04-22 12:00PM	All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy Zacks +9.27%
Mar-29-22 08:02AM	Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors GlobeNewswire +6.82%
Mar-22-22 10:00AM	Wall Street Analysts See a 478% Upside in Nkarta, Inc. (NKTX): Can the Stock Really Move This High? Zacks
Mar-17-22 04:02PM	Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights GlobeNewswire +10.71%
Mar-08-22 04:35PM	Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting GlobeNewswire
Mar-01-22 11:00AM	Biotech leaders call for companies to cut ties to Russia following invasion of Ukraine American City Business Journals
Feb-10-22 08:02AM	Nkarta to Participate at Upcoming Investor Conferences GlobeNewswire
Jan-05-22 06:56AM	Do Institutions Own Nkarta, Inc. (NASDAQ:NKTX) Shares? Simply Wall St.
Dec-16-21 08:02AM	Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML GlobeNewswire
Dec-13-21 04:02PM	Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition GlobeNewswire -6.63%
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital Insider Monkey
Nov-15-21 10:47AM	Can Nkarta (NKTX) Climb 270% to Reach the Level Wall Street Analysts Expect? Zacks -6.55%
Nov-12-21 07:15AM	Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting GlobeNewswire +6.43%
Nov-10-21 04:01PM	Nkarta Reports Third Quarter 2021 Financial Results and Business Update GlobeNewswire
Nov-04-21 08:04AM	Nkarta to Participate at Upcoming Investor Conferences GlobeNewswire
Oct-08-21 08:11AM	Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022 Benzinga -27.57%
Oct-07-21 04:01PM	Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs GlobeNewswire
09:24AM	Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation Simply Wall St.
Oct-01-21 08:08AM	Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting GlobeNewswire
Sep-14-21 08:32AM	Nkarta to Participate at Upcoming Investor Conference GlobeNewswire
Aug-12-21 04:02PM	Nkarta Reports Second Quarter 2021 Financial Results and Business Progress GlobeNewswire
Jul-14-21 09:07AM	Nkarta Unveils Plans For New San Francisco HQ, Manufacturing Site Benzinga
07:00AM	Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters GlobeNewswire
Jun-16-21 07:00AM	Nkarta to Present at Upcoming Investor Conference GlobeNewswire
Jun-14-21 07:01AM	Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term GlobeNewswire +7.19%
Jun-06-21 12:16PM	How Much Will the Nkarta Deal Help CRISPR Therapeutics? Motley Fool
May-25-21 07:30AM	Nkarta Announces June 2021 Investor Conference Schedule GlobeNewswire -6.32%
May-13-21 04:02PM	Nkarta Reports First Quarter 2021 Financial Results and Business Progress GlobeNewswire
May-07-21 11:38AM	Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer Benzinga +6.71%
May-06-21 04:01PM	CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer GlobeNewswire -5.30%
Apr-28-21 08:02AM	Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies GlobeNewswire
Mar-25-21 04:03PM	Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress GlobeNewswire
Feb-17-21 04:03PM	Nkarta Announces February and March 2021 Investor Conference Schedule GlobeNewswire
Dec-09-20 03:46PM	Is NKTX A Good Stock To Buy Now? Insider Monkey +12.57%
Dec-07-20 03:33PM	Fate Stock Soars After Novel Natural-Killer Treatment for Cancers Makes a Splash Barrons.com +21.69%
Nov-12-20 04:03PM	Nkarta Reports Third Quarter 2020 Financial Results GlobeNewswire
04:02PM	Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101 GlobeNewswire
Nov-09-20 08:02AM	Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer GlobeNewswire
Nov-05-20 04:02PM	Nkarta Announces November & December 2020 Investor Conference Schedule GlobeNewswire
Oct-12-20 11:03AM	How Many Nkarta, Inc. (NASDAQ:NKTX) Shares Do Institutions Own? Simply Wall St.
Oct-05-20 04:02PM	Nkarta Announces Leadership Changes GlobeNewswire +8.75%
Sep-29-20 08:02AM	Nkarta Announces October 2020 Investor Conference Schedule GlobeNewswire
Sep-08-20 04:02PM	Nkarta Announces September 2020 Virtual Investor Conference Schedule GlobeNewswire -5.24%
Aug-20-20 04:02PM	Nkarta Reports Second Quarter 2020 Financial Results GlobeNewswire
Jul-31-20 04:42PM	Virtusa, Nkarta See Activist ActionsÁ Barrons.com -5.40%
Jul-14-20 04:39PM	Nkarta raises nearly $290 million in IPO MarketWatch -6.41%
04:15PM	Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares GlobeNewswire
Jul-10-20 11:30AM	Nkarta's stock triples out of the gate, then pulls back MarketWatch
08:09AM	Biotech Nkarta prices IPO at $18 a share, above its price range MarketWatch
12:44AM	Nkarta Announces Pricing of Initial Public Offering GlobeNewswire

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brandenberger Ralph	Sr. VP, Technical Operations	Jun 03	Option Exercise	3.69	4,140	15,278	9,440	Jun 07 04:01 PM
Brandenberger Ralph	Sr. VP, Technical Operations	Jun 03	Sale	15.00	4,140	62,100	5,300	Jun 07 04:01 PM
George Simeon	Director	Apr 28	Buy	15.00	1,333,333	19,999,995	666,667	Apr 29 04:27 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 26	Buy	15.00	2,200,000	33,000,000	7,805,129	Apr 28 04:32 PM
Brandenberger Ralph	Sr. VP, Technical Operations	Dec 01	Option Exercise	3.69	4,140	15,278	4,140	Dec 03 05:02 PM
Brandenberger Ralph	Sr. VP, Technical Operations	Dec 01	Sale	15.64	4,140	64,750	0	Dec 03 05:02 PM
HASTINGS PAUL J	Chief Executive Officer	Sep 29	Sale	27.18	8,500	231,051	219,061	Oct 01 04:35 PM
Brandenberger Ralph	See Remarks	Sep 01	Option Exercise	3.69	4,140	15,278	4,140	Sep 02 08:52 PM
Brandenberger Ralph	See Remarks	Sep 01	Sale	32.08	4,140	132,811	0	Sep 02 08:52 PM
Rajangam Kanya	Chief Medical Officer	Aug 05	Option Exercise	0.41	10,000	4,100	10,000	Aug 09 05:17 PM
Rajangam Kanya	Chief Medical Officer	Aug 05	Sale	37.28	10,000	372,800	0	Aug 09 05:17 PM
Trager James	Chief Scientific Officer	Aug 02	Option Exercise	3.89	2,250	8,752	47,972	Aug 04 04:50 PM
Trager James	Chief Scientific Officer	Aug 02	Sale	31.53	3,600	113,508	44,372	Aug 04 04:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience